Allogeneic Hematopoietic Cell Transplantation for Acute Megakaryocytic Leukemia: A Single Center Study

Acute megakaryocytic leukemia (AMKL) comprises 4-15% of all acute myeloid leukemia (AML) diagnoses in pediatric patients. Unlike patients with Down syndrome who have a>80% expected survival, the 5-year overall survival (OS) in patients with de novo AMKL ranges between 14-49%. While treatment intensification has improved the outcome of these patients over the last few decades, the role of hematopoietic cell transplantation (HCT) in these patients in complete remission (CR) is often debated. To better define the role of HCT, we evaluated the outcomes of pediatric patients who underwent their first HCT at our institution from October 1990 to January 2021.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Shruthi Suryaprakash, Yu Bi, Subodh Selukar, Dinesh Keerthi, Amr Qudeimat, Aimee C. Talleur, Ewelina Mamcarz, Ashok Srinivasan, Renee Madden, Dr. Rebecca Epperly, Swati Naik, Stephen Gottschalk, Brandon M. Triplett, Akshay Sharma Tags: 128 Source Type: research